Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.77 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | NPY1R | P25929 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | NPY2R | P49146 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29876093 | 1.00 | MAPT (0.77) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL29419005 | 1.00 | MAPT (0.77) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL9584082 | 1.00 | MAPT (0.77) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL28692733 | 0.89 | MAPT (0.63) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL2704174 | 0.87 | CYP1A1 (1.00) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL17541840 | 0.87 | MAPT (0.61) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL657392 | 0.87 | MAPT (0.69) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL14416406 | 0.87 | MAPT (0.69) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL7641855 | 0.87 | MAPT (0.69) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL657391 | 0.87 | MAPT (0.69) | MAPTSMN1; SMN2ALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590712-B | Method for preparing epoxide by aerobic epoxidation of olefin by one-pot method | 大连理工大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-108084117-B | Method for preparing epoxide by visible light induction | 大连理工大学 | 2020-06-16 | — | — | CN | disclosed |
| CN-110590712-A | Method for preparing epoxide by aerobic epoxidation of olefin by one-pot method | 大连理工大学 | 2019-12-20 | — | — | CN | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-7816020-B2 | Organic electroluminescent device | NIPPON STEEL CHEMICAL CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080093984-A1 | Organic Electroluminescent Device | NIPPON STEEL & SUMIKIN CHEMICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0662968-B1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES INC (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0662968-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| EP-0662968-A4 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS. | PPG INDUSTRIES INC (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994007889-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5274132-A | Photochromic naphthopyran compounds | TRANSITIONS OPTICAL, INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1111/4885SMN1; SMN2 4881/4885ALDH1A1 1959/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAPT 1274/4885SMN1; SMN2 4881/4885ALDH1A1 1941/4885 |
| US-20030027830-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885SMN1; SMN2 4859/4885ALDH1A1 1324/4885 |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAPT 341/4885SMN1; SMN2 4859/4885ALDH1A1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.